DrugPatentWatch Database Preview
KOVANAZE Drug Profile
Which patents cover Kovanaze, and when can generic versions of Kovanaze launch?
Kovanaze is a drug marketed by St Renatus and is included in one NDA. There are three patents protecting this drug.
This drug has twenty-three patent family members in thirteen countries.
The generic ingredient in KOVANAZE is oxymetazoline hydrochloride; tetracaine hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxymetazoline hydrochloride; tetracaine hydrochloride profile page.
Summary for KOVANAZE
| International Patents: | 23 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | KOVANAZE at DailyMed |
Generic Entry Opportunity Date for KOVANAZE
Generic Entry Date for KOVANAZE*:
Constraining patent/regulatory exclusivity:
NEW COMBINATION NDA:
Dosage:
SPRAY, METERED;NASAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for KOVANAZE
| Drug Class | Ester Local Anesthetic Vasoconstrictor |
| Physiological Effect | Local Anesthesia Vasoconstriction Increased Sympathetic Activity |
Synonyms for KOVANAZE
| Kovacaine |
| Kovacaine Mist |
| Kovacaine Nasal Spray |
| Kovanase |
| Oxymetazoline / tetracaine |
| Oxymetazoline hydrochloride / tetracaine hydrochloride |
| Oxymetazoline hydrochloride mixture with tetracaine hydrochloride |
| S900007440 |
US Patents and Regulatory Information for KOVANAZE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| St Renatus | KOVANAZE | oxymetazoline hydrochloride; tetracaine hydrochloride | SPRAY, METERED;NASAL | 208032-001 | Jun 29, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| St Renatus | KOVANAZE | oxymetazoline hydrochloride; tetracaine hydrochloride | SPRAY, METERED;NASAL | 208032-001 | Jun 29, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| St Renatus | KOVANAZE | oxymetazoline hydrochloride; tetracaine hydrochloride | SPRAY, METERED;NASAL | 208032-001 | Jun 29, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for KOVANAZE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 201309321 | ➤ Try a Free Trial |
| China | 103932973 | ➤ Try a Free Trial |
| South Korea | 20120042729 | ➤ Try a Free Trial |
| Country | Patent Number | Estimated Expiration |
